Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease

Fig. 2

Fexofenadine ameliorates dopaminergic neuronal cell death in 6-OHDA mouse model. a Schematic diagram of in vivo 6-OHDA experiment. b Behavioral results of mice in the bridge, pole and cylinder tests at 3–4 months after PBS, PBS + Fexofenadine (Fexo), 6-OHDA, or 6-OHDA + Fexo groups. c IHC of TH in striatum (Cpu) and analysis of striatal TH density in PBS, PBS + Fexo, 6-OHDA, or 6-OHDA + Fexo. d IHC of TH in substantia nigra (SN) and analysis of stereology counts of TH-positive neurons in PBS (n = 13), PBS + Fexo (n = 5), 6-OHDA (n = 12), or 6-OHDA + Fexo (n = 12) groups. Scale bar indicates 200 μm. ***p < 0.001, **p < 0.01, *p < 0.05, one-way ANOVA with Tukey’s multiple comparison test

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094